Silo Pharma (SILO) announced the filing of a provisional patent application with the U.S. Patent and Trademark Office. This application, focused on its lead asset SPC-15, highlights Silo’s commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder. The provisional patent covers the chronic, combinatorial targeting of N-methyl-D-aspartate receptors and serotonin type IV receptors to extend behavioral effects against stress-induced perseverative behavior and hyponeophagia. This filing adds to Silo’s growing portfolio of pending patents for SPC-15 technology, originally licensed through a collaboration with Columbia University. This exclusive agreement enables Silo to develop, manufacture, and commercialize SPC-15 globally.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.